Bortezomib

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12012 publications

Hematopoietic stem cell transplantation for multiple myeloma in Kazakhstan: Ten-year single-center experience.

Hematopoietic stem cell transplantation for multiple myeloma in Kazakhstan: Ten-year single-center experience.

Journal: The Journal of international medical research

Published: January 23, 2026

Frequency-adjusted daratumumab-based regimen versus bortezomib/dexamethasone in newly diagnosed AL amyloidosis: a matched-cohort study.

Frequency-adjusted daratumumab-based regimen versus bortezomib/dexamethasone in newly diagnosed AL amyloidosis: a matched-cohort study.

Journal: Annals of medicine

Published: January 21, 2026

Multiple Myeloma Management in a Large Low- and Middle-Income Country: Lessons From India in Balancing Cost and Clinical Efficacy in Resource-Limited Settings.

Multiple Myeloma Management in a Large Low- and Middle-Income Country: Lessons From India in Balancing Cost and Clinical Efficacy in Resource-Limited Settings.

Journal: JCO oncology practice

Published: January 12, 2026

Structure-Based Design of Pan-Selective Peptide Epoxyketones for the Three Human Immunoproteasome Active Sites.

Structure-Based Design of Pan-Selective Peptide Epoxyketones for the Three Human Immunoproteasome Active Sites.

Journal: Journal of medicinal chemistry

Published: January 08, 2026

Clinical Analysis of Ixazomib-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Multiple Myeloma with 1q21 Amplification

Clinical Analysis of Ixazomib-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Multiple Myeloma with 1q21 Amplification

Journal: Zhongguo shi yan xue ye xue za zhi

Published: January 08, 2026

Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.

Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 06, 2026

Effect of different induction chemotherapy regimens on autologous hematopoietic stem cell mobilization in patients with multiple myeloma in the new drug era

Effect of different induction chemotherapy regimens on autologous hematopoietic stem cell mobilization in patients with multiple myeloma in the new drug era

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: January 05, 2026

Immune-Suppressed, Not Immune-Cold: HMOX1-CD14-Immunoproteasome Axis and Structure-Guided Combination Pharmacotherapies in Isocitrate Dehydrogenase-Mutant Glioblastoma.

Immune-Suppressed, Not Immune-Cold: HMOX1-CD14-Immunoproteasome Axis and Structure-Guided Combination Pharmacotherapies in Isocitrate Dehydrogenase-Mutant Glioblastoma.

Journal: Omics : a journal of integrative biology

Published: December 30, 2025

Computer prediction and genetic analysis identifies retinoic acid modulation as a driver of conserved longevity pathways in genetically diverse Caenorhabditis nematodes.

Computer prediction and genetic analysis identifies retinoic acid modulation as a driver of conserved longevity pathways in genetically diverse Caenorhabditis nematodes.

Journal: eLife

Published: December 23, 2025

RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myeloma.

RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myeloma.

Journal: Cancer biology & therapy

Published: December 18, 2025

The role and molecular mechanism of transcription factor EB and its target genes in multiple myeloma treatment with bortezomib

The role and molecular mechanism of transcription factor EB and its target genes in multiple myeloma treatment with bortezomib

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: December 17, 2025

Daratumumab bortezomib and dexamethasone in transplant ineligible newly diagnosed elderly myeloma patients (AMN006)-a trial by Asian Myeloma Network (NCT03695744).

Daratumumab bortezomib and dexamethasone in transplant ineligible newly diagnosed elderly myeloma patients (AMN006)-a trial by Asian Myeloma Network (NCT03695744).

Journal: Leukemia & lymphoma

Published: December 16, 2025

Showing 1-12 of 12,012

Last Updated: 02/24/2026